Hemophilia, sickle cell disease (SCD), and beta-thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies. To understand the appropriate and cost-effective use of treatments for inherited blood disorders, AMCP convened an expert panel of managed care stakeholders in October 2022.
Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis.
AMCP applauds Congress for passing the Pre-approval Information Exchange (PIE) Act of 2022. This bipartisan bill will enhance proactive information-sharing on new treatments between drug manufacturers and health plans.
December 2022 Legislative & Regulatory Briefing: The PIE Act Makes Waves in Washington D.C.; Member Benefit! Read the Latest Regulatory NewsBREAKs; AMCP CEO Susan A. Cantrell Applauds Reintroduction of the PIE Act; AMCP Joins Pharmacy Organizations in Request for Medicaid Guidance to States; AMCP's Adam Colborn Featured in Politico Pro.
Review this sponsored webinar to understand how to utilize real-time continuous glucose monitoring (RT-CGM) and overcome barriers for improved glycemic outcomes that may help social determinants of health inequities.